Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ESTA vs ALGN vs INMD vs NVCR vs AEYE

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ESTA
Establishment Labs Holdings Inc.

Medical - Devices

HealthcareNASDAQ • CR
Market Cap$2.12B
5Y Perf.+266.0%
ALGN
Align Technology, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$12.06B
5Y Perf.-31.4%
INMD
InMode Ltd.

Medical - Devices

HealthcareNASDAQ • IL
Market Cap$882M
5Y Perf.-5.0%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-75.0%
AEYE
AudioEye, Inc.

Software - Application

TechnologyNASDAQ • US
Market Cap$100M
5Y Perf.-4.5%

ESTA vs ALGN vs INMD vs NVCR vs AEYE — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ESTA logoESTA
ALGN logoALGN
INMD logoINMD
NVCR logoNVCR
AEYE logoAEYE
IndustryMedical - DevicesMedical - DevicesMedical - DevicesMedical - Instruments & SuppliesSoftware - Application
Market Cap$2.12B$12.06B$882M$1.92B$100M
Revenue (TTM)$211M$4.10B$375M$674M$40M
Net Income (TTM)$-51M$430M$87M$-173M$-3M
Gross Margin69.3%67.7%77.8%75.2%78.3%
Operating Margin-18.5%14.4%21.3%-27.2%-7.9%
Forward P/E14.9x9.6x
Total Debt$264M$114M$13M$290M$721K
Cash & Equiv.$76M$1.08B$303M$103M$5M

ESTA vs ALGN vs INMD vs NVCR vs AEYELong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ESTA
ALGN
INMD
NVCR
AEYE
StockMay 20May 26Return
Establishment Labs … (ESTA)100366.0+266.0%
Align Technology, I… (ALGN)10068.6-31.4%
InMode Ltd. (INMD)10095.0-5.0%
NovoCure Limited (NVCR)10025.0-75.0%
AudioEye, Inc. (AEYE)10095.5-4.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: ESTA vs ALGN vs INMD vs NVCR vs AEYE

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INMD leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Establishment Labs Holdings Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ESTA
Establishment Labs Holdings Inc.
The Growth Play

ESTA is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 27.1%, EPS growth 42.7%, 3Y rev CAGR 9.3%
  • 191.0% 10Y total return vs ALGN's 122.8%
  • 27.1% revenue growth vs INMD's -6.2%
  • +116.5% vs AEYE's -27.9%
Best for: growth exposure and long-term compounding
ALGN
Align Technology, Inc.
The Value Angle

ALGN plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
INMD
InMode Ltd.
The Income Pick

INMD carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 1.04
  • Lower volatility, beta 1.04, Low D/E 1.9%, current ratio 9.88x
  • Beta 1.04, current ratio 9.88x
  • Better valuation composite
Best for: income & stability and sleep-well-at-night
NVCR
NovoCure Limited
The Healthcare Pick

NVCR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
AEYE
AudioEye, Inc.
The Technology Pick

Among these 5 stocks, AEYE doesn't own a clear edge in any measured category.

Best for: technology exposure
See the full category breakdown
CategoryWinnerWhy
GrowthESTA logoESTA27.1% revenue growth vs INMD's -6.2%
ValueINMD logoINMDBetter valuation composite
Quality / MarginsINMD logoINMD23.3% margin vs NVCR's -25.7%
Stability / SafetyINMD logoINMDBeta 1.04 vs AEYE's 2.29, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)ESTA logoESTA+116.5% vs AEYE's -27.9%
Efficiency (ROA)INMD logoINMD11.8% ROA vs NVCR's -16.5%, ROIC 13.5% vs -16.4%

ESTA vs ALGN vs INMD vs NVCR vs AEYE — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ESTAEstablishment Labs Holdings Inc.

Segment breakdown not available.

ALGNAlign Technology, Inc.
FY 2025
Clear Aligner
80.4%$3.2B
Scanners And Services
19.6%$790M
INMDInMode Ltd.
FY 2025
Capital Equipment
100.0%$289M
NVCRNovoCure Limited

Segment breakdown not available.

AEYEAudioEye, Inc.
FY 2024
Enterprise
100.0%$15M

ESTA vs ALGN vs INMD vs NVCR vs AEYE — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINMDLAGGINGAEYE

Income & Cash Flow (Last 12 Months)

INMD leads this category, winning 3 of 6 comparable metrics.

ALGN is the larger business by revenue, generating $4.1B annually — 101.6x AEYE's $40M. INMD is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, ESTA holds the edge at +45.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricESTA logoESTAEstablishment Lab…ALGN logoALGNAlign Technology,…INMD logoINMDInMode Ltd.NVCR logoNVCRNovoCure LimitedAEYE logoAEYEAudioEye, Inc.
RevenueTrailing 12 months$211M$4.1B$375M$674M$40M
EBITDAEarnings before interest/tax-$32M$790M$81M-$165M-$504,000
Net IncomeAfter-tax profit-$51M$430M$87M-$173M-$3M
Free Cash FlowCash after capex-$57M$717M$91M-$48M$2M
Gross MarginGross profit ÷ Revenue+69.3%+67.7%+77.8%+75.2%+78.3%
Operating MarginEBIT ÷ Revenue-18.5%+14.4%+21.3%-27.2%-7.9%
Net MarginNet income ÷ Revenue-24.2%+10.5%+23.3%-25.7%-7.6%
FCF MarginFCF ÷ Revenue-27.2%+17.5%+24.2%-7.1%+5.5%
Rev. Growth (YoY)Latest quarter vs prior year+45.2%+6.2%+5.3%+12.3%+7.9%
EPS Growth (YoY)Latest quarter vs prior year+92.6%+23.6%-30.8%-100.0%+29.0%
INMD leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

INMD leads this category, winning 5 of 6 comparable metrics.

At 9.7x trailing earnings, INMD trades at a 67% valuation discount to ALGN's 29.8x P/E. On an enterprise value basis, INMD's 6.9x EV/EBITDA is more attractive than ALGN's 13.9x.

MetricESTA logoESTAEstablishment Lab…ALGN logoALGNAlign Technology,…INMD logoINMDInMode Ltd.NVCR logoNVCRNovoCure LimitedAEYE logoAEYEAudioEye, Inc.
Market CapShares × price$2.1B$12.1B$882M$1.9B$100M
Enterprise ValueMkt cap + debt − cash$2.3B$11.1B$593M$2.1B$96M
Trailing P/EPrice ÷ TTM EPS-41.88x29.80x9.73x-13.80x-32.36x
Forward P/EPrice ÷ next-FY EPS est.14.85x9.64x
PEG RatioP/E ÷ EPS growth rate0.98x
EV / EBITDAEnterprise value multiple13.92x6.88x
Price / SalesMarket cap ÷ Revenue10.03x2.99x2.38x2.92x2.49x
Price / BookPrice ÷ Book value/share90.61x3.02x1.33x5.51x20.91x
Price / FCFMarket cap ÷ FCF24.57x10.46x
INMD leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

ALGN leads this category, winning 5 of 9 comparable metrics.

INMD delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-2 for ESTA. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ESTA's 11.23x. On the Piotroski fundamental quality scale (0–9), ALGN scores 7/9 vs INMD's 3/9, reflecting strong financial health.

MetricESTA logoESTAEstablishment Lab…ALGN logoALGNAlign Technology,…INMD logoINMDInMode Ltd.NVCR logoNVCRNovoCure LimitedAEYE logoAEYEAudioEye, Inc.
ROE (TTM)Return on equity-2.0%+10.7%+13.3%-50.8%-47.8%
ROA (TTM)Return on assets-15.0%+6.9%+11.8%-16.5%-9.5%
ROICReturn on invested capital-14.6%+15.4%+13.5%-16.4%-42.4%
ROCEReturn on capital employed-14.1%+14.5%+12.1%-28.9%-17.7%
Piotroski ScoreFundamental quality 0–947354
Debt / EquityFinancial leverage11.23x0.03x0.02x0.85x0.15x
Net DebtTotal debt minus cash$189M-$965M-$289M$187M-$5M
Cash & Equiv.Liquid assets$76M$1.1B$303M$103M$5M
Total DebtShort + long-term debt$264M$114M$13M$290M$721,000
Interest CoverageEBIT ÷ Interest expense-1.30x389.13x-96.80x-2.79x
ALGN leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ESTA leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ESTA five years ago would be worth $10,061 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, ESTA leads with a +116.5% total return vs AEYE's -27.9%. The 3-year compound annual growth rate (CAGR) favors AEYE at 6.4% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricESTA logoESTAEstablishment Lab…ALGN logoALGNAlign Technology,…INMD logoINMDInMode Ltd.NVCR logoNVCRNovoCure LimitedAEYE logoAEYEAudioEye, Inc.
YTD ReturnYear-to-date+4.6%+7.9%-5.9%+28.3%-18.7%
1-Year ReturnPast 12 months+116.5%-2.2%-2.1%+1.1%-27.9%
3-Year ReturnCumulative with dividends+6.4%-45.0%-60.2%-75.7%+20.6%
5-Year ReturnCumulative with dividends+0.6%-71.9%-63.9%-91.3%-60.2%
10-Year ReturnCumulative with dividends+191.0%+122.8%+105.0%+30.3%+102.2%
CAGR (3Y)Annualised 3-year return+2.1%-18.1%-26.4%-37.6%+6.4%
ESTA leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ESTA and INMD each lead in 1 of 2 comparable metrics.

INMD is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than AEYE's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ESTA currently trades 86.5% from its 52-week high vs AEYE's 49.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricESTA logoESTAEstablishment Lab…ALGN logoALGNAlign Technology,…INMD logoINMDInMode Ltd.NVCR logoNVCRNovoCure LimitedAEYE logoAEYEAudioEye, Inc.
Beta (5Y)Sensitivity to S&P 5001.30x1.66x1.04x2.20x2.29x
52-Week HighHighest price in past year$83.31$208.31$16.74$20.06$16.39
52-Week LowLowest price in past year$32.75$122.00$12.72$9.82$5.31
% of 52W HighCurrent price vs 52-week peak+86.5%+80.8%+83.2%+83.9%+49.4%
RSI (14)Momentum oscillator 0–10066.844.639.869.861.3
Avg Volume (50D)Average daily shares traded455K1.1M804K1.5M194K
Evenly matched — ESTA and INMD each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: ESTA as "Buy", ALGN as "Buy", INMD as "Buy", NVCR as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 14.9% for INMD (target: $16).

MetricESTA logoESTAEstablishment Lab…ALGN logoALGNAlign Technology,…INMD logoINMDInMode Ltd.NVCR logoNVCRNovoCure LimitedAEYE logoAEYEAudioEye, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$85.00$203.60$16.00$33.50
# AnalystsCovering analysts14331115
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+3.9%+14.5%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

INMD leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). ALGN leads in 1 (Profitability & Efficiency). 1 tied.

Best OverallInMode Ltd. (INMD)Leads 2 of 6 categories
Loading custom metrics...

ESTA vs ALGN vs INMD vs NVCR vs AEYE: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ESTA or ALGN or INMD or NVCR or AEYE a better buy right now?

For growth investors, Establishment Labs Holdings Inc.

(ESTA) is the stronger pick with 27. 1% revenue growth year-over-year, versus -6. 2% for InMode Ltd. (INMD). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate Establishment Labs Holdings Inc. (ESTA) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ESTA or ALGN or INMD or NVCR or AEYE?

On trailing P/E, InMode Ltd.

(INMD) is the cheapest at 9. 7x versus Align Technology, Inc. at 29. 8x. On forward P/E, InMode Ltd. is actually cheaper at 9. 6x.

03

Which is the better long-term investment — ESTA or ALGN or INMD or NVCR or AEYE?

Over the past 5 years, Establishment Labs Holdings Inc.

(ESTA) delivered a total return of +0. 6%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ESTA returned +191. 0% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ESTA or ALGN or INMD or NVCR or AEYE?

By beta (market sensitivity over 5 years), InMode Ltd.

(INMD) is the lower-risk stock at 1. 04β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 120% more volatile than INMD relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 11% for Establishment Labs Holdings Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ESTA or ALGN or INMD or NVCR or AEYE?

By revenue growth (latest reported year), Establishment Labs Holdings Inc.

(ESTA) is pulling ahead at 27. 1% versus -6. 2% for InMode Ltd. (INMD). On earnings-per-share growth, the picture is similar: Establishment Labs Holdings Inc. grew EPS 42. 7% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, AEYE leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ESTA or ALGN or INMD or NVCR or AEYE?

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -24. 2% for Establishment Labs Holdings Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ESTA or ALGN or INMD or NVCR or AEYE more undervalued right now?

On forward earnings alone, InMode Ltd.

(INMD) trades at 9. 6x forward P/E versus 14. 9x for Align Technology, Inc. — 5. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

08

Which pays a better dividend — ESTA or ALGN or INMD or NVCR or AEYE?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is ESTA or ALGN or INMD or NVCR or AEYE better for a retirement portfolio?

For long-horizon retirement investors, InMode Ltd.

(INMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +105. 0% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INMD: +105. 0%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ESTA and ALGN and INMD and NVCR and AEYE?

These companies operate in different sectors (ESTA (Healthcare) and ALGN (Healthcare) and INMD (Healthcare) and NVCR (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ESTA is a small-cap high-growth stock; ALGN is a mid-cap quality compounder stock; INMD is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ESTA

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 22%
  • Gross Margin > 41%
Run This Screen
Stocks Like

ALGN

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Stocks Like

INMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 13%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

AEYE

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 46%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ESTA and ALGN and INMD and NVCR and AEYE on the metrics below

Revenue Growth>
%
(ESTA: 45.2% · ALGN: 6.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.